Evidence map›Paper›PMID 28258492›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors.

H Yin, C Qin, Y Zhao, Y Du, Z Sheng, Q Wang, Q Song, L Chen, C Liu, T Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Clinical Significance of SOX10 Expression in Human Pathology.Current issues in molecular biology · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

H YinDepartment of Urology, Peking University People's Hospital, The Second Clinical Medical College of Peking University, No. 11, Xi Zhi Men Nan Street, Beijing, 100044, China.
C QinDepartment of Urology, Peking University International Hospital, Beijing, China.
Y ZhaoDepartment of Urology, Central Hospital of Qingdao City, Qingdao, China.
Y DuDepartment of Urology, Peking University People's Hospital, The Second Clinical Medical College of Peking University, No. 11, Xi Zhi Men Nan Street, Beijing, 100044, China.
Z ShengDepartment of Urology, Peking University People's Hospital, The Second Clinical Medical College of Peking University, No. 11, Xi Zhi Men Nan Street, Beijing, 100044, China.
Q WangDepartment of Urology, Peking University People's Hospital, The Second Clinical Medical College of Peking University, No. 11, Xi Zhi Men Nan Street, Beijing, 100044, China.
Q SongDepartment of Urology, Peking University People's Hospital, The Second Clinical Medical College of Peking University, No. 11, Xi Zhi Men Nan Street, Beijing, 100044, China.
L ChenDepartment of Urology, Central Hospital of Qingdao City, Qingdao, China.
C LiuDepartment of Urology, Central Hospital of Qingdao City, Qingdao, China.
T XuDepartment of Urology, Peking University People's Hospital, The Second Clinical Medical College of Peking University, No. 11, Xi Zhi Men Nan Street, Beijing, 100044, China. xutao@medmail.com.cn.
Peking University People's Hospital · CNPeking University · CNQingdao Municipal Hospital · CNPeking University International Hospital · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo detect the expression level and significance of SOX10 in human bladder cancer.

methodsImmunohistochemical analyses were performed to assess SOX10 protein level using a bladder cancer tissue microarray (including 59 spots of cancer tissues and 46 spots of paired normal tissues) and 31 specimens and to define the relationship between SOX10 and clinicopathological bladder cancer characteristics in patients. SOX10 protein and mRNA levels in bladder cancer cell lines (T24, 5637, BIU87, EJ) and transitional cell papilloma cell line (RT4) were tested by western blotting and quantitative real-time PCR (q-PCR), respectively. Cell Counting Kit-8 (CCK-8) and colony formation assays were performed to investigate bladder cancer cell proliferation after SOX10 knockdown. The effect of SOX10 on cell migration and invasion was analyzed by Transwell and Matrigel assays. Kaplan-Meier survival curves and Cox regression analyses were used to evaluate SOX10 prognostic significance for bladder cancer patients. The mechanisms by which SOX10 promote bladder cancer progression were examined by western blotting.

resultsSOX10 protein was upregulated in 74.4% of bladder cancer tissues compared with adjacent normal tissues (32.6%). SOX10 protein was also upregulated in malignant cell lines. In addition, high SOX10 expression was related with clinical stage (P = 0.008), T stage (P = 0.004), histological grade (P = 0.002) and lymph node metastasis (P = 0.006). Kaplan-Meier survival curves and Cox regression analyses showed that SOX10 functioned as an independent prognostic factor for overall survival. SOX10 knockdown in bladder cancer cells significantly impacted proliferation, migration and invasion, and SOX10 might promote bladder cancer progression by altering β-catenin and Met expression.

conclusionSOX10 was over-expressed in bladder cancer and promoted malignant bladder cancer cell behaviors. SOX10 has potential as a molecular target for bladder cancer treatment.

Indexed as

Gene Expression Regulation, NeoplasticAgedBiomarkers, TumorCarcinoma, Transitional CellCase-Control StudiesCell MovementCell ProliferationFemaleFollow-Up StudiesHumansLymphatic MetastasisMalePrognosisSOXE Transcription FactorsSurvival RateTumor Cells, CulturedBiomarkers, TumorSOX10 protein, humanSOXE Transcription FactorsBladder cancerCell proliferationInvasionSOX10Therapeutic target

Identifiers

PMID28258492
OpenAlexW2594617004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.